Advertisement

Topics

Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

09:46 EDT 10 Aug 2017 | Labiotech.eu

Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in Phase IIa for its candidate GLPG1690, which aims to treat ...

This awesome article Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

NEXT ARTICLE

More From BioPortfolio on "Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market"

Quick Search
Advertisement
 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...